Liquidia settles all litigation with United Therapeutics

Morrisville, North Carolina - Liquidia Corporation has reached an agreement with United Therapeutics to settle six lawsuits, according to a press release. The deal involves the payment of $380.7 million in installments from Liquidia to United Therapeutics over 2026 and 2027. The first payment of $175 million will be made within 30 business days, followed by two equal installments of $72.7 million.

The settlement was reached after a September 30, 2026, court ruling that deemed patent claims valid and found infringement by Liquidia. This patent pertains to the treatment of pulmonary hypertension linked with interstitial lung disease using inhaled treprostinil. As part of the arrangement, Liquidia removed the PH-ILD indication from its YUTREPIA label and halted promotion of that use.

Despite this, YUTREPIA, which is approved for treating pulmonary arterial hypertension, will continue to be accessible to patients. The settlement resolves claims of patent infringement, trade secret misappropriation, and antitrust litigation. Liquidia paid $60.3 million to parties involved in the antitrust litigation related to Treprostinil Injection.

The company has also terminated its promotional agreement for that product. As of September 30, 2026, Liquidia's preliminary, unaudited third-quarter YUTREPIA net product sales were $222.7 million, and its cash and cash equivalents amounted to $396.1 million. The company expects to cover the settlement payments through ongoing YUTREPIA sales and its existing cash reserves.

The settlement includes mutual releases and does not constitute an admission of liability by either party.